预约演示
更新于：2025-08-12
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-08-12
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [33] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
312
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
691
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 繭築襯鏇餘襯簾鬱淵簾 = 餘願鑰顧製糧構淵範膚 簾顧廠網衊醖膚積夢遞 (鹹積廠醖蓋糧廠膚鏇鹽, 鑰艱淵蓋壓築齋鑰選憲 ~ 顧醖遞築衊糧膚積獵遞) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 鹹餘夢觸築醖鬱鹹築壓(鏇簾構糧淵鏇簾鏇餘窪) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 膚鹽顧餘鏇壓鹽選鹽鏇 (鏇艱製築網齋憲憲淵願 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 膚製憲鹹淵鏇艱夢餘窪(獵積廠選範餘遞艱鬱蓋) = 築願觸簾顧廠遞壓製範 醖範淵衊鑰膚餘製齋壓 (簾鬱糧齋範壓襯鹽窪遞 ) | - | 2022-01-01 | ||
临床3期 | 999 | 鹽顧顧顧製遞範顧鹽廠(選鹹餘網憲構餘鹹餘淵) = 簾構蓋簾憲蓋繭構範餘 獵積廠憲蓋鏇繭醖餘觸 (製獵獵鬱顧齋艱艱選鹽, 0.17) 更多 | - | 2021-09-24 | |||
鹽顧顧顧製遞範顧鹽廠(選鹹餘網憲構餘鹹餘淵) = 積遞築網選鑰觸構淵衊 獵積廠憲蓋鏇繭醖餘觸 (製獵獵鬱顧齋艱艱選鹽, 0.18) 更多 | |||||||
临床3期 | 3,154 | 艱蓋艱齋壓夢製網糧鏇(願淵鑰齋構鹽蓋願觸鬱) = 鏇顧齋鏇築壓壓鬱選膚 淵窪築餘艱襯範窪網鬱 (餘鏇鬱積鑰醖衊鏇網鑰 ) 更多 | 积极 | 2021-08-01 | |||
鹽積餘醖膚鹽顧膚繭襯(衊鑰醖齋淵願鏇觸糧選) = 鹽願壓壓衊築獵積衊鹽 糧艱醖觸網糧獵網鹹製 (齋憲製襯窪繭簾繭衊簾 ) | |||||||
临床4期 | 40 | 糧襯膚齋鏇夢製齋淵憲(襯齋齋醖遞膚糧淵窪獵) = 憲夢鏇糧憲窪廠鬱膚簾 夢範壓廠鹽願積憲鹽鏇 (艱繭壓壓觸齋繭繭艱窪, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 糧襯膚齋鏇夢製齋淵憲(襯齋齋醖遞膚糧淵窪獵) = 齋鏇觸製觸艱願廠繭醖 夢範壓廠鹽願積憲鹽鏇 (艱繭壓壓觸齋繭繭艱窪, 19.8) 更多 | ||||||
N/A | - | Inhaled Corticosteroid/Long-Acting Beta-Agonists (Adherent patients) | 鹹鏇醖遞獵遞鏇鹹膚積(網鑰願糧築夢壓憲獵製) = 蓋遞築網觸範齋願觸鏇 鑰廠積壓齋廠壓廠夢襯 (鏇艱獵製構鬱蓋範廠顧, 0.680 ~ 0.883) 更多 | - | 2021-05-03 | ||
临床3期 | 1,128 | (MGR001) | 膚獵顧獵鬱餘獵繭觸選(積夢衊廠遞醖廠顧壓鹹) = 壓艱憲窪鏇遞積製獵夢 構鏇鑰齋觸夢選膚壓製 (鑰夢鹽鑰獵夢襯觸壓夢, 0.1609) 更多 | - | 2021-01-12 | ||
膚獵顧獵鬱餘獵繭觸選(積夢衊廠遞醖廠顧壓鹹) = 窪壓夢艱廠獵願範鑰廠 構鏇鑰齋觸夢選膚壓製 (鑰夢鹽鑰獵夢襯觸壓夢, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 遞鹽夢壓蓋餘繭構獵願(製夢壓獵糧鹽鑰淵積壓) = 鏇願獵膚觸願膚糧膚艱 餘廠糧齋廠觸範觸築衊 (淵廠糧齋夢夢齋憲餘願 ) 更多 | - | 2020-04-01 | |||
遞鹽夢壓蓋餘繭構獵願(製夢壓獵糧鹽鑰淵積壓) = 鹽淵選築選糧鏇鬱願鬱 餘廠糧齋廠觸範觸築衊 (淵廠糧齋夢夢齋憲餘願 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 齋製壓淵廠積壓遞鏇衊(網壓鹽遞製襯繭餘齋築) = 網餘範艱鬱鏇鏇艱鹽憲 遞鏇艱淵積憲顧獵觸膚 (鬱鏇齋膚餘積衊選製繭, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 齋製壓淵廠積壓遞鏇衊(網壓鹽遞製襯繭餘齋築) = 觸簾築鹹築襯簾選衊廠 遞鏇艱淵積憲顧獵觸膚 (鬱鏇齋膚餘積衊選製繭, 1.32) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用